Disclosures for "Patient Experience With Once-daily Deutetrabenazine Extended-release Tablets for the Treatment of Tardive Dyskinesia in Individuals With Prior Valbenazine Use "
-
Dr. Jain has received personal compensation in the range of $1,000,000+ for serving as a Consultant for AbbVie, Acadia, Adamas, Alfasigma, Alkermes, Almatica, Axsome, Biogen, Boehringer Ingleheim, Corium, Cingulate Therapeutics, Eisai, Evidera, Impel, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Osmotica, Otsuka, Pamlab, Pfizer, Sage Therapeutics, Shire, Sumitomo, Sunovion, Supernus, Takeda, Teva, Transcend Therapeutics and Viatris. Dr. Jain has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Usona. Dr. Jain has received personal compensation in the range of $1,000,000+ for serving on a Speakers Bureau for AbbVie, Alkermes, Almatica, Axsome, Corium, Eisai, Indivior, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Takeda, Teva, Tris Pharmaceuticals and Viatris.
-
Martijn Konings has received personal compensation for serving as an employee of Teva Pharmaceuticals. Martijn Konings has stock in Teva Pharmaceuticals.
-
Author has nothing to disclose
-
Mr. Kotak has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Teva.
-
Pooja Gandhi has received personal compensation for serving as an employee of Teva Pharmaceuticals. Pooja Gandhi has stock in Teva Pharmaceuticals.